RxDoctor Payments Data

Grayce Selig

Medical Oncology · Paoli, PANPI 1497242069

Payments from drug & device makers

What this record shows

This record is dominated by other: $1,196 of the $1,738 with a category attached, or 68.8%. Novartis accounts for 76.6% of it on its own, with 13 other manufacturers making up the rest. That places this record below the midpoint for medical oncology clinicians in PA, where the typical reported total is $2,595.

$1,738in general payments, 2019–2025

Across 34 payments — averaging $51.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$78
  • Tempus AI, Inc$62
  • Pfizer$37
  • AVEO Pharmaceuticals, Inc.$34
  • Eisai Inc.$32
  • plus $164 from 8 others

What the payments were for

  • Food & beverage$54231%
  • Other$1,19669%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,738 in reported general payments places this provider in the 40th percentile of 238 medical oncology providers in Pennsylvania.

See all medical oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$28,434
Medicare patients
109
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Paoli

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →